Evidence map›Paper›PMID 31222759›Full record

ArticleJournal of inherited metabolic disease2020

The effectiveness of correcting abnormal metabolic profiles.

Peter Theodore Clayton

Open access · hybridAbstract read
In one paragraph

Article in Journal of inherited metabolic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Healthy Patients WithJPGN reports · 2023
    Article
  5. Article
  6. The effectiveness of correcting abnormal metabolic profiles.Journal of inherited metabolic disease · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Peter Theodore ClaytonUCL Great Ormond Street Institute of Child Health, London, UK.ORCID 0000-0001-7592-4302
Great Ormond Street Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inborn errors of metabolism cause disease because of accumulation of a metabolite before the blocked step or deficiency of an essential metabolite downstream of the block. Treatments can be directed at reducing the levels of a toxic metabolite or correcting a metabolite deficiency. Many disorders have been treated successfully first in a single patient because we can measure the metabolites and adjust treatment to get them as close as possible to the normal range. Examples are drawn from Komrower's description of treatment of homocystinuria and the author's trials of treatment in bile acid synthesis disorders (3β-hydroxy-Δ

Indexed as

3-Hydroxysteroid DehydrogenasesAdministration, OralBile Acids and SaltsEpilepsyHumansMetabolic DiseasesPyridoxal PhosphatePyridoxaminephosphate OxidasePyridoxineRandomized Controlled Trials as TopicVitamin B 6Vitamin B 6 Deficiency3-Hydroxysteroid DehydrogenasesBile Acids and SaltsPyridoxal PhosphatePyridoxaminephosphate OxidasePyridoxineVitamin B 6bile acid synthesis disordershomocystinuriaN = 1 trialsneurotransmitter aminespersonalised medicinepyridoxal phosphaterandomised controlled trialstreatmentvitamin B6

Identifiers

PMID31222759
PMCPMC7041635
OpenAlexW2950075962

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.